On April 2, 2026, Elite Pharmaceuticals, Inc. announced the commercial launch of its generic version of methadone hydrochloride tablets in 5 mg and 10 mg dosages. This product is marketed under the Elite Laboratories, Inc. label and is indicated for the management of severe and persistent pain that requires an opioid analgesic. Methadone is also utilized for detoxification and maintenance treatment of opioid addiction. The launch is expected to tap into a market with annual retail sales of approximately $22 million based on IQVIA data from 2025. This strategic move aligns with Elite's focus on developing niche generic products and is anticipated to enhance the company's revenue streams. The press release detailing this launch has been filed as Exhibit 99.1 in the company's Form 8-K, which serves as a current report under the Securities Exchange Act of 1934. The information provided in the filing is not considered 'filed' for purposes of the Exchange Act and is not incorporated by reference into any of Elite's filings under the Securities Act. This launch is a significant step for Elite Pharmaceuticals as it continues to expand its product offerings in the competitive pharmaceutical market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.